263 related articles for article (PubMed ID: 22343918)
1. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma.
Xie L; Ushmorov A; Leithäuser F; Guan H; Steidl C; Färbinger J; Pelzer C; Vogel MJ; Maier HJ; Gascoyne RD; Möller P; Wirth T
Blood; 2012 Apr; 119(15):3503-11. PubMed ID: 22343918
[TBL] [Abstract][Full Text] [Related]
2. FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma.
Vogel MJ; Xie L; Guan H; Tooze RM; Maier T; Kostezka U; Maier HJ; Holzmann K; Chan FC; Steidl C; Reichel JB; Weitzer CD; Gehringer F; Kick AB; Cesarman E; Roshal M; Gascoyne RD; Möller P; Wirth T; Ushmorov A
Blood; 2014 Nov; 124(20):3118-29. PubMed ID: 25232062
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
4. KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma.
Guan H; Xie L; Leithäuser F; Flossbach L; Möller P; Wirth T; Ushmorov A
Blood; 2010 Sep; 116(9):1469-78. PubMed ID: 20519630
[TBL] [Abstract][Full Text] [Related]
5. Fine-tuning of FOXO3A in cHL as a survival mechanism and a hallmark of abortive plasma cell differentiation.
Osswald CD; Xie L; Guan H; Herrmann F; Pick SM; Vogel MJ; Gehringer F; Chan FC; Steidl C; Wirth T; Ushmorov A
Blood; 2018 Apr; 131(14):1556-1567. PubMed ID: 29439954
[TBL] [Abstract][Full Text] [Related]
6. c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma.
Leventaki V; Drakos E; Karanikou M; Psatha K; Lin P; Schlette E; Eliopoulos A; Vassilakopoulos TP; Papadaki H; Patsouris E; Medeiros LJ; Rassidakis GZ
Hum Pathol; 2014 Mar; 45(3):565-72. PubMed ID: 24457077
[TBL] [Abstract][Full Text] [Related]
7. The Tumor Suppressive mir-148a Is Epigenetically Inactivated in Classical Hodgkin Lymphoma.
Paczkowska J; Janiszewska J; Bein J; Schneider M; Bednarek K; Ustaszewski A; Hartmann S; Hansmann ML; Giefing M
Cells; 2020 Oct; 9(10):. PubMed ID: 33066457
[TBL] [Abstract][Full Text] [Related]
8. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
Szydlowski M; Kiliszek P; Sewastianik T; Jablonska E; Bialopiotrowicz E; Gorniak P; Polak A; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Malenda A; Lech-Maranda E; Warzocha K; Juszczynski P
Blood; 2016 Feb; 127(6):739-48. PubMed ID: 26585955
[TBL] [Abstract][Full Text] [Related]
9. Repression of TCF3/E2A contributes to Hodgkin lymphomagenesis.
Guan H; Xie L; Wirth T; Ushmorov A
Oncotarget; 2016 Jun; 7(24):36854-36864. PubMed ID: 27166193
[TBL] [Abstract][Full Text] [Related]
10. FOXO1 downregulation contributes to the oncogenic program of primary mediastinal B-cell lymphoma.
Xie L; Ritz O; Leithäuser F; Guan H; Färbinger J; Weitzer CD; Gehringer F; Bruederlein S; Holzmann K; Vogel MJ; Möller P; Wirth T; Ushmorov A
Oncotarget; 2014 Jul; 5(14):5392-402. PubMed ID: 24977668
[TBL] [Abstract][Full Text] [Related]
11. Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells.
Janz M; Hummel M; Truss M; Wollert-Wulf B; Mathas S; Jöhrens K; Hagemeier C; Bommert K; Stein H; Dörken B; Bargou RC
Blood; 2006 Mar; 107(6):2536-9. PubMed ID: 16263788
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA High Throughput Loss-of-Function Screening Reveals an Oncogenic Role for miR-21-5p in Hodgkin Lymphoma.
Yuan Y; Niu F; Nolte IM; Koerts J; de Jong D; Rutgers B; Osinga J; Azkanaz M; Terpstra M; Bystrykh L; Diepstra A; Visser L; Dzikiewicz-Krawczyk A; Kok K; Kluiver J; van den Berg A
Cell Physiol Biochem; 2018; 49(1):144-159. PubMed ID: 30184526
[TBL] [Abstract][Full Text] [Related]
13. FOXO in B-cell lymphopoiesis and B cell neoplasia.
Ushmorov A; Wirth T
Semin Cancer Biol; 2018 Jun; 50():132-141. PubMed ID: 28774833
[TBL] [Abstract][Full Text] [Related]
14. Nuclear forkhead box O1 controls and integrates key signaling pathways in hepatocytes.
Naïmi M; Gautier N; Chaussade C; Valverde AM; Accili D; Van Obberghen E
Endocrinology; 2007 May; 148(5):2424-34. PubMed ID: 17303659
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of MircoRNA-370 induces proliferation in human prostate cancer cells by downregulating the transcription factor FOXO1.
Wu Z; Sun H; Zeng W; He J; Mao X
PLoS One; 2012; 7(9):e45825. PubMed ID: 23029264
[TBL] [Abstract][Full Text] [Related]
16. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma.
Tiacci E; Döring C; Brune V; van Noesel CJ; Klapper W; Mechtersheimer G; Falini B; Küppers R; Hansmann ML
Blood; 2012 Nov; 120(23):4609-20. PubMed ID: 22955914
[TBL] [Abstract][Full Text] [Related]
17. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.
Rodig SJ; Ouyang J; Juszczynski P; Currie T; Law K; Neuberg DS; Rabinovich GA; Shipp MA; Kutok JL
Clin Cancer Res; 2008 Jun; 14(11):3338-44. PubMed ID: 18519761
[TBL] [Abstract][Full Text] [Related]
18. Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs.
Van Vlierberghe P; De Weer A; Mestdagh P; Feys T; De Preter K; De Paepe P; Lambein K; Vandesompele J; Van Roy N; Verhasselt B; Poppe B; Speleman F
Br J Haematol; 2009 Dec; 147(5):686-90. PubMed ID: 19775296
[TBL] [Abstract][Full Text] [Related]
19. An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.
Lollies A; Hartmann S; Schneider M; Bracht T; Weiß AL; Arnolds J; Klein-Hitpass L; Sitek B; Hansmann ML; Küppers R; Weniger MA
Leukemia; 2018 Jan; 32(1):92-101. PubMed ID: 28659618
[TBL] [Abstract][Full Text] [Related]
20. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas.
Loddenkemper C; Anagnostopoulos I; Hummel M; Jöhrens-Leder K; Foss HD; Jundt F; Wirth T; Dörken B; Stein H
J Pathol; 2004 Jan; 202(1):60-9. PubMed ID: 14694522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
